SEARCH

SEARCH BY CITATION

References

  • 1
    Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. HEPATOLOGY 2005; 42: 14141419.
  • 2
    De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4: 928940.
  • 3
    van Bömmel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. HEPATOLOGY 2002; 36: 507508.
  • 4
    Núñez M, Pérez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 23524.
  • 5
    Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348: 1778.
  • 6
    van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004; 40: 14211425.
  • 7
    Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. HEPATOLOGY 2006; 44: 11101116.
  • 8
    van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005; 12: 364372.
  • 9
    van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir rescue therapy for patients with lamivudine-resistant hepatitis B virus (HBV) infection showing persistent high level replication during adefovir therapy. HEPATOLOGY 2006; 44: 318325.
  • 10
    Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, van Bömmel F, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20: 19511954.
  • 11
    Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 24422455.
  • 12
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191201.
  • 13
    Qi X, Xiong S, Yang H, Miller M, Delaney WE III. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355362.
  • 14
    Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 24712477.
  • 15
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. HEPATOLOGY 1998; 27: 16701677.
  • 16
    Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus DNA in two international reference plasma preparations. HEPATOLOGY 2001; 33: 751757.
  • 17
    Norder H, Hammas B, Löfdahl S, Courouce' AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992; 73: 12011208.
  • 18
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353363.
  • 19
    Yang H, Qi X, Sobogai A, Miller M, Xiong S, Delaney WE IV. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625633.
  • 20
    Berg T, Möller B, Trinh H, Chan S, Marcellin P, Suarez E, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV) [Abstract]. J Hepatol 2008; 48: 34A.
  • 21
    van Bömmel F, Trojan J, Feucht HH, Möller B, Hüppe D, Wiedenmann B, et al. Tenofovir shows limited efficacy in treatment of HBV infections resistant against adefovir [Abstract]. HEPATOLOGY 2007; 46: 664A.
  • 22
    Snow-Lampart A, Sorbel J, Chappell B, Curtis M, Zuh Y, Borroto-Esoda K. Lack of tenofovir DF (TDF) resistance mutations in treatment-naïve and treatment-experienced subjects with chronic HBV infection following 48 weeks of TDF mono-therapy. EASL-AASLD-APASL-IASL Conference Hepatitis B&C virus resistance to antiviral therapies. Paris, France; February 14–16, 2008. Abstract.
  • 23
    Cornberg M, Protzer U, Dollinger MM, Petersen J, Wedemeyer H, Berg T. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2007; 45: 12811328.
  • 24
    Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391398.